Japanese Foundation for Cancer Research
Koto, Tokyo, Japan
Medical laboratory in the Koto, Tokyo
3 Chome-8-31 Ariake, Koto City, Tokyo 135-0063
About Japanese Foundation for Cancer Research
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Loxo Oncology, Inc.
7
Boehringer Ingelheim
5
Pfizer
5
Eli Lilly and Company
2
Kyowa Kirin, Inc.
1
Clinical Trials at Japanese Foundation for Cancer Research
During the past decade, Japanese Foundation for Cancer Research conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 3 clinical trials were completed, i.e. on
average, 17.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
2008-07-04
2010-03-10
Completed
10
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
2009-07-30
2013-06-27
Completed
81
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
2012-11-01
2021-02-17
Completed
372
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
2017-05-02
2024-09-01
Recruiting
875
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
2018-02-23
2023-08-04
Active, not recruiting
146
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
2020-02-17
2027-07-01
Active, not recruiting
250
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
2020-02-11
2026-11-13
Recruiting
400
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
2020-12-21
2026-11-15
Recruiting
815
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Japanese Foundation for Cancer Research" #1 sponsor was "Loxo Oncology, Inc." with 7 trials, followed by "Boehringer Ingelheim" with 5 trials
sponsored, "Pfizer" with 5 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Kyowa Kirin, Inc."
with 2 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Foundation for Cancer Research"
#1 collaborator was "Eli Lilly and Company" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Japanese Foundation for Cancer Research
According to Clinical.Site data, the most researched conditions in "Japanese Foundation for Cancer Research" are
"Breast Neoplasms" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Lymphoma" (2 trials), "Medullary Thyroid Cancer" (2 trials) and "Neoplasms" (2 trials). Many other conditions were trialed in "Japanese Foundation for Cancer Research" in a lesser frequency.
Clinical Trials Intervention Types at Japanese Foundation for Cancer Research
Most popular intervention types in "Japanese Foundation for Cancer Research" are "Drug" (20 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Selpercatinib" (3 trials), "BI 3011441" (2 trials), "Cetuximab" (2 trials), "Inotuzumab Ozogamicin (CMC-544)" (2 trials) and "Pemetrexed" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Japanese Foundation for Cancer Research
The vast majority of trials in "Japanese Foundation for Cancer Research" are
20 trials for "All" genders.
Clinical Trials Status at Japanese Foundation for Cancer Research
Currently, there are NaN active trials in "Japanese Foundation for Cancer Research".
undefined are not yet recruiting,
12 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Japanese Foundation for Cancer Research,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Japanese Foundation for Cancer Research, 6 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 12 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".
Departments of Japanese Foundation for Cancer Research
Japanese Foundation for Cancer Research has several departments that took part in Clinical trials: "Cancer Institute Hospital" - 7 trials, "The Cancer Institute Hospital of JFCR" - 207 trials, "The Cancer Inst. Hosp. of JFCR; Breast Oncology Center" - 5 trials
Departments List
Name
City
Trials